Тетяна Вадимівна Ащеулова
Kharkiv National Medical University · 424 works · 64 citations · h-index 6
Top works
- Early prediction of long COVID-19 syndrome persistence at 12 months after hospitalisation: a prospective observational study from Ukraine
- Beneficial effects of combined therapy with lacidipine and candesartan in obese hypertensive patients
- Short-term echocardiographic follow-up after hospitalization for COVID-19: a focus on early post-acute changes
- Peculiarities of the influence of antihypertensive therapy on endothelial function, oxidative stress and immune activation in obese patients
- [NESFATIN-1 ACTIVITY IN PATIENTS WITH ESSENTIAL HYPERTENSION AND PREDIABETES, TYPE 2 DIABETES].
- A prognostic model and pre-discharge predictors of post-COVID-19 syndrome after hospitalization for SARS-CoV-2 infection
- Oncostatin M, Interleukin-6, Glucometabolic Parameters and Lipid Profile in Hypertensive Patients with Prediabetes and Type 2 Diabetes Mellitus
- Диастолическая дисфункция: от открытия до последних обновлений
- Effects of antihypertensive treatment on systemic inflammation, oxidative stress and proinflammatory cytokine levels
- LEFT VENTRICULAR REMODELING IN HYPERTENSION: EVOLUTION OF THE APPROACH
- Carbohydrate and lipid disorders and adipokines levels in relation to body mass index in hypertensive patients
- Endothelial immune activation and functional state in patients with hypertensive disease
- Relationships of oxidative stress and systemic inflammation markers depending on the degree and duration of hypertension
- Dislipidemia: definition, diagnostics and treatment
- PATHOGENETIC ADVANCES OF FOSINOPRIL SODIUM WITH HYDROCHLOROTHIAZIDE IN OBESE HYPERTENSIVE PATIENTS.
- PATHOGENETIC ROLE OF MYOCARDIAL FIBROSIS: FOCUS ON EXTRACELLULAR MATRIX
- PREVENTIVE CARDIOLOGY, PRECLINICAL DIAGNOSES: OLD PROBLEMS – NEW APPROACHES
- 12-Month trajectories of physical and mental symptom scores after COVID-19 hospitalization and their role in predicting “very long” COVID
- Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure
- Poster session Thursday 6 December - AM: Other myocardial diseases